Interpretation and discussion of the 2023 expert consensus statement on practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries
The cardio-renal protective effect of sodium-glucose contransporter-2(SGLT-2)inhibitors has been extensively studied and validated through numerous large-scale,multi-center clinical trials.The A-sia Pacific Society of Nephrology updated and published an expert consensus statement in April 2023.It has considered the distinct culture and customs of Asian Pacific region and has focused on providing guidelines for clinicians including the indications,common adverse effects,and important considerations for the use of SGLT-2 inhibitors.The editorial board has proposed nine specific recommendations and two flow charts to in-crease clinicians'confidence in initiating SGLT-2 inhibitors and to enhance their ability to effectively manage patients who may benefit from this class of drugs.
万方数据
维普
